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Abstract 
Background: The molecular prognostic markers and carcinogenesis of intrahepatic cholangiocarcinoma (ICC) have 
not been well documented. The purpose of this study was to investigate the prognostic value of the eyes absent 
homolog 4 (EYA4) gene in ICC and its biological effects on ICC growth in vitro and in vivo.
Methods: One hundred twelve patients with ICC who underwent hepatectomy were enrolled in the study. EYA4 
mRNA and EYA4 protein levels in ICC and adjacent non‑tumoral tissues were evaluated using real‑time quantitative 
polymerase chain reaction and immunohistochemical staining, respectively. EYA4 protein levels in ICC cells were 
determined using western blot analysis. The associations between EYA4 expression and clinicopathologic features of 
ICC were analyzed. To identify independent prognostic factors, univariate and multivariate analyses were performed. 
The biological effects of EYA4 on ICC cells were evaluated by establishing stable EYA4‑overexpressing transfectants 
in vitro, and EYA4’s effects on tumor growth were evaluated by intra‑tumoral injection of EYA4‑expressing plasmids in 
a NOD/SCID murine model of xenograft tumors.
Results: ICC tissues had significantly lower EYA4 mRNA and protein levels compared with adjacent non‑tumoral tis‑
sues (both P < 0.001). Univariate and multivariate analyses showed that EYA4 protein level, tumor number, adjacent 
organ invasion, lymph node metastasis, and tumor differentiation were independent prognostic factors for disease‑
free survival and overall survival (all P < 0.05). In vitro, EYA4 overexpression inhibited tumor cell growth, foci formation, 
and cell invasiveness. In vivo, intra‑tumoral injection of EYA4‑expressing plasmids significantly inhibited ICC growth in 
the murine xenograft model compared with the control group (P < 0.05).
Conclusion: EYA4 gene functioned as a molecular prognostic marker in ICC, and its overexpression inhibited tumor 
growth in vitro and in vivo.
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Background
Over the past four decades, intrahepatic cholangiocarci-
noma (ICC) has had a rising incidence worldwide [1, 2]. 
Surgical resection offers a chance for cure for patients 
with ICC, however its long-term outcome is still dis-
mal due to a high incidence of postoperative tumor 
recurrence and metastases. The 5-year overall survival 
(OS) rate of ICC patients has been found to be only 
15.0%–30.7% [3–5]. Although some clinicopathologic 
parameters, including serum carbohydrate antigen 19-9 
(CA19-9) level, tumor number, adjacent organ invasion, 
lymph node metastasis, and tumor differentiation, have 
been shown to be prognostic factors for ICC [5–7], the 
molecular prognostic markers and potential mecha-
nisms of ICC have not been well documented. Elucidat-
ing the molecular prognostic markers of ICC would be 
clinically and scientifically significant, since it would help 
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researchers understand the carcinogenesis of ICC and 
offer potential therapeutic targets.
Eyes absent homolog 4 (EYA4) is a member of the EYA 
gene family, which, in mammals, contains four members: 
EYA1, EYA2, EYA3, and EYA4. The EYA gene family was 
first discovered in drosophila eye development, in which 
its mutation or deletion led to the “eyeless” phenotype, 
and its mis-expression led to the formation of ectopic eye 
tissue [8, 9]. Some studies showed that EYA family mem-
bers could combine with sine oculis (SIX1) and dachs-
hund (DACH) to function as transcriptional factors to 
regulate specific gene expression in mammalian organo-
genesis [10, 11]. In addition, EYA family members had 
dual functions of threonine and tyrosine phosphatases 
[11–14]. However, its implications in carcinogenesis are 
unclear.
Using DNA methylation microarray, our previous 
study showed that the EYA4 gene was markedly hyper-
methylated in hepatocellular carcinoma (HCC) tissues 
compared with adjacent non-tumorous tissues [15]. Low 
EYA4 expression in HCC tissues was associated with 
short disease-free survival (DFS) and OS, and multivari-
ate analysis showed that EYA4 expression was an inde-
pendent prognostic factor in HCC patients [15]. These 
results suggested that the EYA4 gene might play an 
important role in tumor occurrence and progression, but 
its prognostic value in ICC and its biological effects on 
ICC cells remain unknown.
The purpose of this study was to assess, by univariate 
and multivariate survival analyses, the prognostic value 
of the EYA4 gene in ICC and to investigate its biological 
effects on ICC cells in vitro and in vivo.
Methods
Patients and specimens
One hundred and twelve patients with histologically 
proven ICC, who underwent curative hepatectomy at 
the First Affiliated Hospital of Sun Yat-sen University, 
in Guangzhou, Guangdong, China between June 2006 
and June 2012, were included in this study. The inclusion 
criteria of the study were as follows: (1) histologically 
diagnosed ICC; (2) curative resection of tumors; and (3) 
absence of distant metastases. The patients who met one 
of the following criteria were excluded from the study: (1) 
perihilar cholangiocarcinoma (Klatskin tumor); (2) mix 
tumors of HCC and ICC; (3) R1 or R2 resection or lapa-
rotomy with tumor biopsy; and (4) receiving neoadjuvant 
chemotherapy and/or radiotherapy.
Of the 112 patients included in this study, 63 (56.2%) 
were men, and 49 (43.8%) were women, with a median 
age of 57 years (range, 28–79 years). Eighty-six patients 
(76.8%) had a single tumor; the remaining 26 patients 
(23.2%) had multiple tumors. Tumor size ranged from 
1.0 to 16.0  cm in diameter (median, 5.7  cm). Fourteen 
patients (12.5%) had adjacent organ invasion. Forty-nine 
patients (43.8%) had lymph node metastasis. Seventy 
patients (62.5%) had an elevated level of serum CA19-9 
(>37 U/L), and 43 (38.4%) had an elevated serum level of 
carcino-embryonic antigen (CEA) (>5 µg/L). All patients 
underwent curative hepatectomy with regional lymph 
node dissection. According to the American Joint Com-
mittee on Cancer (AJCC) Cancer Staging Manual (7th 
edition) [16], of the 112 ICC patients, 43 (38.4%) had 
tumor-node-metastasis (TNM) stage I disease, 10 (8.9%) 
had TNM stage II disease, 6 (5.4%) had TNM stage III 
disease, and 53 (47.3%) had TMN stage IV disease.
Patients were followed up every 1–3  months, end-
ing in March 2014. Tumor recurrence/metastasis was 
diagnosed on the basis of dynamic imaging results (i.e., 
contrast-enhanced computed tomography and/or con-
trast-enhanced magnetic resonance imaging and/or con-
trast-enhanced ultrasonography), and serum CA19-9 and 
CEA levels.
For 48 patients, tumorous and adjacent non-tumorous 
tissues were collected, snap-frozen instantly in liquid 
nitrogen, and stored at −80  °C for molecular biologi-
cal analysis. Paraffin-embedded ICC specimens of 112 
patients that were used for immunohistochemical stain-
ing were obtained from the Department of Pathology, 
First Affiliated Hospital of Sun Yat-sen University.
This study was approved by the Ethics Committee 
of the First Affiliated Hospital of Sun Yat-sen Univer-
sity. Written informed consent was obtained from each 
patient.
Real‑time quantitative polymerase chain reaction 
(RT‑qPCR)
Using RNAiso (TaKaRa, Dalian, Liaoning, China), 
total RNA was extracted from 48 pairs of tumorous 
and adjacent non-tumorous tissues as well as cultured 
cells. Using the PrimeScript® RT Reagent kit (TaKaRa), 
reverse transcription was performed with 0.5 μg of total 
RNA. RT-qPCR was performed to examine the mRNA 
level of EYA4 using TaKaRa SYBR® Premix Ex Taq™ Kit 
(TaKaRa) and the ABI PRISM® 7900HT RT-qPCR Sys-
tem (Applied Biosystems, Carlsbad, CA, USA). Glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) gene 
was used as endogenous control. Primers were listed as 
follows: EYA4 sense 5′-GAATAACACAGCCGATGG-3′, 
antisense 5′-CCAGGTCACTATCAGGAG-3′; GAPDH 
sense 5′-GCACCGTCAAGGCTGAGAAC-3′, antisense 
5′-TGGTGAAGACGCCAGTGGA-3′. Thermocycling 
conditions for PCR were as follows: an initial cycle of 
95 °C for 5 min, followed by 40 cycles of 95 °C for 30 s, 
95 °C for 5 s, and 65 °C for 30 s, and finally 72 °C for 5 min 
for the extension. ΔCt (difference in cycle threshold) 
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was calculated for each sample (ΔCt  =  CtTarget gene   
−  CtGAPDH), and relative quantities were compared. All 
reactions were repeated in triplicate.
Immunohistochemical (IHC) staining
Paraffin-embedded tissues were cut into 4-μm sections 
and mounted on glass slides. IHC analysis was performed 
on 112 ICC tissues to detect EYA4 protein. Briefly, tissues 
were deparaffinized in dimethylbenzene, rehydrated in 
graded alcohol, and then incubated in 3% H2O2 to block 
endogenous peroxidase activity. Antigen retrieval was 
achieved by treating the tissues with citrate buffer in a 
pressure cooker. Tissues were subsequently incubated 
with rabbit anti-human EYA4 polyclonal antibodies 
(dilution 1:25; Abcam, Cambridge, UK) at 4 °C overnight. 
A ChemMate™ Envision™ Detection Kit (Dako, Glostrup, 
Denmark) was used to detect and visualize the bound pri-
mary antibodies. Human skeletal muscle tissue was used 
as positive control for EYA4 antibody (recommended by 
supplier), and the rabbit IgG antibody (Biosynthesis, Bei-
jing, China) was used as negative control in IHC stain-
ing. Staining intensity (negative, 0; mild, 1; moderate, 2; 
and severe, 3) and proportion of positive cells (negative, 
0; ≤10, 1; >10 and ≤33%, 2; >33 and ≤66%, 3; and >66%, 
4) were quantified, respectively [17]. Summation of the 
scores of the two parameters represents protein expres-
sion level. Each slide was scored by two observers inde-
pendently, and the average of their scores was recorded 
as the IHC score.
Cell lines
Human ICC cell lines RBE and SSP-25 were obtained 
from the Cell Resources Center of Shanghai Institutes for 
Biological Science, Chinese Academy of Science (Shang-
hai, China). Cells were cultured in RPMI-1640 (Gibco 
BRL, Rockville, MD, USA) and supplemented with 10% 
fetal bovine serum (Gibco BRL).
Western blotting
Total cell lysates were prepared using a KeyGEN Total 
Protein Extraction Kit (Nanjing, Jiangsu, China). Aliquots 
of 10–20  μL cell lysates were electrophoresed in 10% 
sodium dodecyl sulfate polyacrylamide gel electrophores 
(SDS-PAGE), and proteins were transferred onto polyvi-
nylidene fluoride (PVDF) membrane (Merck Millipore, 
Cambridge, UK). The membrane was blocked, incubated 
with primary antibody at 4 °C overnight, and then incu-
bated with secondary antibody at room temperature for 
30  min. Rabbit anti-human EYA4 polyclonal antibodies 
(dilution 1:300; Abcam), GAPDH monoclonal antibody, 
and goat anti-rabbit secondary antibody (dilution 1:3000; 
Biosynthesis) were used to detect EYA4 and GAPDH 
protein. GAPDH was used as loading control. Bands were 
visualized using an ECL kit (KeyGEN, Nanjing, China) 
and exposed to Kodak X-OMAT film (Carestream Health 
Inc., Rochester, NY, USA).
Establishment of stable EYA4‑overexpressing transfectants 
of ICC cells
The pReceiver-M02 empty vector and the recombinant 
pReceiver-M02/EYA4 overexpression plasmids (U0188) 
were purchased from Genecopoeia (Rockville, MD, 
USA). The recombinant EYA4-expressing plasmid was 
transfected into RBE and SSP-25 cells at 70%–80% con-
fluence using Lipofectamine™ 2000 (Invitrogen, Carls-
bad, CA, USA). Plasmid pReceiver-M02 was used as 
control (FulenGen, Guangzhou, Guangdong, China). 
After 2 weeks of G418 selection, stable transfected cells 
were subjected to limited dilution. Survival clones with 
the highest expression of EYA4 in both cell lines were 
used for further studies. Stable EYA4-overexpressing 
transfectants and vector transfectants of RBE and SSP-
25 cells were designated as RBE-EYA4, RBE-Vector, SSP-
EYA4, and SSP-Vector, respectively.
Cell proliferation assay
Cells were seeded into 96-well plates at the density of 
2000 cells per well. Cell proliferation was detected at 
24, 48, 72, and 96  h after seeding using Cell Counting 
Kit-8 (Dojindo, Kumamoto, Japan). Absorbance values 
at 450 nm (A450) were recorded as representation of cell 
viability. Each experiment was done in triplicate, and four 
individual experiments were performed.
Foci formation assay
Cells were seeded into 6-well plates at the density of 1000 
cells per well and cultured for 7 days. After fixing in 4% 
paraformaldehyde and staining with 1% crystal violet, 
foci with more than 50 cells were counted. Four inde-
pendent experiments were performed.
Cell invasion assay
Cell invasion assay was performed with BD BioCoat™ 
Tumor Invasion System (BD Biosciences, Bedford, MA, 
USA). Approximately 5 × 104 cells/chamber were seeded 
into the rehydrated chamber. After 22  h of incubation, 
cells that invaded to the bottom surface of the chamber 
were fixed and stained as mentioned above, then counted 
under the microscope. Four assays were performed.
In vivo experiments using xenograft ICC in NOD/SCID mice
The cultured RBE and SSP-25 cells were trypsinized 
and resuspended to a density of 1 × 108 cells/mL. Then, 
1 ×  107 RBE or SSP-25 cells in 100  µL were inoculated 
subcutaneously into both flanks of 4–5-week male NOD/
SCID mice (HFK Bioscience Co. Ltd, Beijing, China). 
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After the xenograft tumors reached 6  mm in diameter 
(or volume  >100  mm3), the RBE and SSP-25 tumor-
bearing mice were randomized into EYA4, vector, and 
blank groups (in each group, there were three mice bear-
ing 5 tumors) and subjected to the following treatments, 
respectively. (1) EYA4 group: intra-tumoral injection 
of lipofactamine 2000, EYA4-expressing plasmids, and 
Opti-MEM; (2) Vector group: intra-tumoral injection of 
lipofactamine 2000, vector-plasmids, and Opti-MEM; 
and (3) Blank group: intra-tumoral injection of lipo-
fectamine 2000 and Opti-MEM. Each injection contained 
20 μg plasmid (1 μg/μL) mixed with 40 μL lipofectamine 
2000 and 20 μL Opti-MEM in EYA4 and vector groups; 
in blank group, 40  μL lipofectamine 2000 mixed with 
2  μL Opti-MEM was injected each time. The treatment 
was repeated every 5  days and given a total of 6 times. 
Body weights of mice and the tumor size were monitored 
every 3  days. Tumor volume was calculated as follows: 
volume (mm3) =  length × width2/2. On post-treatment 
day 30, the mice were euthanized, and their tumors were 
removed and weighed. The in  vivo experiments were 
approved by the Ethics Committee of the First Affiliated 
Hospital of Sun Yat-sen University.
Statistical analysis
Results were presented as mean  ±  standard deviation 
(SD) or median (range). Statistical analysis was per-
formed using SPSS 17.0 software (IBM, Chicago, IL, 
USA). DFS was calculated from the date of surgery to 
the date that tumor recurrences or metastases were con-
firmed. OS was defined as the interval between the date 
of surgery and death or the date of last follow-up. DFS 
and OS were calculated using the Kaplan–Meier method. 
The associations between EYA4 protein expression and 
clinicopathologic parameters were analyzed using the 
Mann–Whitney U test. Univariate and multivariate Cox 
regression analyses were used to identify independent 
prognostic factors. Inter-group comparisons of foci for-
mation, cell invasion ability, mice weight, and xenograft 
tumor size and weight were done using Student’s t test. 
Cell proliferation and the xenograft tumor growth curve 
were compared among groups by repeated measures of 
analysis of variance. Two-sided P < 0.05 values were con-
sidered statistically significant.
Results
Postoperative tumor recurrence and survival
Of the 112 patients, 107 (95.5%) had a regular follow-
up, with a median follow-up of 13.9  months (range, 
2.5–71.7  months). The remaining 5 patients defaulted 
after a follow-up of 8.0, 13.0, 15.0, 18.3, and 24.0 months, 
respectively. Tumor recurrence developed in 83 patients, 
with a median time to recurrence of 5.5 months (range, 
1.0–32.0  months). Seventy-six patients died dur-
ing follow-up, with a median survival of 11.5  months 
(range, 2.5–42.0  months). The 1-, 3-, and 5-year DFS 
rates were 47.7%, 22.0% and 22.0%, respectively; the 1-, 
3-, and 5-year OS rates were 64.3%, 30.5% and 23.1%, 
respectively.
EYA4 expression in ICC tissues and its clinical values
EYA4 mRNA level in ICC tissues was significantly lower 
than that in adjacent non-tumorous tissues, with a 
median ΔCt of 13.14 (range, 8.45–17.03) vs 11.77 (range, 
7.38–14.87; P  <  0.001; Fig.  1a). Consistently, EYA4 pro-
tein level in ICC tissues was significantly lower than that 
in non-tumorous tissues, with a median IHC score of 3.4 
(range, 0.7–6.6) vs 5.7 (range, 3.7–7.1; P < 0.001; Fig. 1b–
g). With respect to associations between EYA4 expres-
sion and clinicopathologic features, multiple tumors had 
a lower EYA4 protein level than single tumors, with a 
median IHC score of 3.2 (range, 0.7–6.6) vs 3.5 (range, 
1.1–6.6; P  =  0.023; Fig.  1h). Furthermore, tumors with 
lymph node metastases had a lower EYA4 protein level 
than tumors without lymph node metastases, with a 
median IHC score of 3.2 (range, 0.7–6.5) vs 3.6 (range, 
2.0–6.6; P < 0.001; Fig. 1i).
Univariate analysis showed that EYA4 protein level, 
serum CA19-9 level, serum CEA level, tumor number, 
adjacent organ invasion, lymph node metastasis, and 
tumor differentiation were prognostic factors for DFS 
and OS (Fig. 2). Multivariate analysis showed that EYA4 
protein level, tumor number, adjacent organ invasion, 
lymph node metastasis, and tumor tumor differentiation 
were independent prognostic factors for DFS and OS 
(Table 1). These results suggest that the EYA4 gene might 
play an important role in ICC progression.
EYA4 overexpression suppressed growth of ICC cells 
in vitro
Using two stable EYA4-overexpressing transfectants of 
ICC cell lines RBE-EYA4 and SSP-EYA4, we studied the 
biological effects of the EYA4 gene on ICC cells. RT-
qPCR showed that EYA4 mRNA levels in RBE-EYA4 
and SSP-EYA4 cells were significantly up-regulated 
compared with that of their vector control transfectants 
(19.14 ±  5.51-fold for RBE-EYA4, 24.04 ±  0.65-fold for 
SSP-EYA4; both P  <  0.001; Fig.  3a). Consistently, West-
ern blot analysis showed that EYA4 protein levels in RBE-
EYA4 and SSP-EYA4 were much higher than those in 
RBE-vector and SSP-vector, respectively (Fig. 3a).
Using cell proliferation assays, foci formation assays, 
and cell invasion assays, we evaluated the biological 
effects of the EYA4 gene on ICC cells. Cell proliferation 
assays showed that overexpression of EYA4 significantly 
inhibited the growth rate of ICC cells (P = 0.001 for both 
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cell lines; Fig.  3b). The frequencies of foci formation in 
RBE-EYA4 and SSP-EYA4 were significantly lower than 
those in RBE-Vector and SSP-Vector, with a foci num-
ber of 126.0 ±  5.6 vs 236.3 ±  9.1 for RBE-EYA4, and a 
foci number of 84.3 ± 8.0 vs 192.0 ± 10.2 for SSP-EYA4 
(both P < 0.001; Fig. 3c). Cell invasion assays showed that 
the number of invaded RBE-EYA4 and SSP-EYA4 cells 
were significantly lower than that of invaded RBE-Vector 
and SSP-Vector cells, with a cell number of 33.0 ± 5.3 vs 
98.6 ± 9.0 for REB-EYA4, and a cell number of 20.6 ± 3.8 
vs 62.6  ±  5.8 for SSP-EYA4 (both P  <  0.001; Fig.  3d). 
These data suggest that overexpression of EYA4 had con-
siderable tumor-suppressive effects on ICC cells.
Intra‑tumoral injection of EYA4‑expressing plasmids 
inhibited the growth of xenograft ICC in NOD/SCID mice
Intra-tumoral injection of EYA4-expressing plasmids 
(EYA4 group) significantly suppressed the growth of 
both RBE and SSP-25 xenograft ICC in NOD/SCID mice 
since day 3 after treatment as compared with vector plas-
mids (vector group) and blank control (blank group) 
(P  =  0.001 for RBE and P  =  0.033 for SSP-25; Fig.  4a). 
On day 30 after treatment, the mean volume of tumors 
in the EYA4 group was significantly smaller than those 
in the vector group and blank group, with a tumor vol-
ume of 463.8 ±  327.4  mm3 vs 2369.3 ±  564.3  mm3 and 
2337.0 ± 693.6 mm3 in RBE xenograft tumors (P = 0.001; 
Fig. 1 Eyes absent homolog 4 (EYA4) mRNA and protein expression in intrahepatic cholangiocarcinoma (ICC) tissues. a Boxplot of EYA4 real‑time 
quantitative polymerase chain reaction shows that ICC tissues have lower EYA4 mRNA levels than non‑tumorous adjacent liver tissues (*P < 0.001). 
ΔCt stands for difference in cycle threshold; it was calculated as follows: ΔCt = CtTarget gene − CtGAPDH. b Positive control staining of human skeleton 
muscle tissue using EYA4 antibody. c Negative control staining of human skeleton muscle using rabbit IgG as the primary antibody. d Boxplot of 
EYA4 immunohistochemical (IHC) scores shows that ICC tissues have lower EYA4 protein level than non‑tumorous adjacent liver tissues (*P < 0.001). 
e A typical staining of adjacent non‑tumorous liver tissue. f A weak staining in tumor tissues with lymph node metastasis. g A strong staining in 
tumor tissues without lymph node metastasis. Black arrows indicate positive staining of hepatocytes and ICC cells. L liver. T tumor. M muscle. h 
Boxplot of EYA4 IHC scores shows that multiple tumors have lower EYA4 protein levels than single tumors (*P = 0.023). i Boxplot of EYA4 IHC scores 
shows that tumor with lymph node metastasis have lower EYA4 protein levels than those without lymph node metastasis (*P < 0.001)
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Fig. 4b), and 366.0 ± 161.2 mm3 vs 940.8 ± 355.9 mm3 and 
988.8 ±  452.8 mm3 in SSP xenograft tumors (P =  0.011; 
Fig.  4b). Consistently, the weight of tumors in the EYA4 
group was significantly lower than those in the vector and 
blank groups, both in RBE and SSP-25 xenograft tumors 
(P = 0.004 for RBE and P = 0.036 for SSP-25; Fig. 4c). With 
respect to the adverse effects of intra-tumoral injection 
of EYA4-expressing plasmids, there were no differences 
in the weights of mice among the three groups in both 
RBE tumors (P =  0.617) and SSP-25 tumors (P =  0.924; 
Fig. 4d). The in vivo results confirmed the tumor-suppres-
sive effects of the EYA4 gene on ICC cells.
Discussion
In the present study, we showed that the expression of 
EYA4 gene was down-regulated in ICC tissues and its 
expression level was an independent prognostic factor 
for patients with ICC undergone hepatectomy. Overex-
pression of EYA4 gene could inhibit the growth of ICC 
cells in  vitro and vivo. These results implied that the 
Fig. 2 Disease‑free survival (DFS) and overall survival (OS) curves of 112 ICC patients. a DFS curves of the 112 ICC patients show that patients with 
lower EYA4 protein levels, serum carbohydrate antigen 19‑9 (CA19‑9) level >37 U/L, serum CEA level >5 µg/L, multiple tumors, adjacent organ 
invasion, lymph node metastasis, and poor differentiation had worse DFS (all P < 0.05). b OS curves of the 112 ICC patients show that patients with 
lower EYA4 protein levels, serum CA19‑9 level >37 U/L, serum CEA level >5 µg/L, multiple tumors, adjacent organ invasion, lymph node metastasis, 
and poor differentiation had worse OS (all P < 0.05)
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Table 1 Prognostic factors for  DFS and  OS of  patients with  intrahepatic cholangiocarcinoma determined by  using uni-
variate and multivariate Cox regression models
EYA4 Eyes absent homolog 4; CA19-9 carbohydrate antigen 19-9; CEA carcino-embryonic antigen; DFS disease-free survival; OS overall survival; HR hazard ratio; CI 
confidence interval
a Immunohistochemical (IHC) score, split at median
Variable DFS OS
HR 95% CI P value HR 95% CI P value
Univariate
Sex (women vs. men) 0.820 0.532–1.265 0.370 0.853 0.549–1.324 0.478
Age (<65 years vs. ≥65 years) 1.088 0.659–1.797 0.741 0.984 0.583–1.661 0.953
Liver cirrhosis (yes vs. no) 1.410 0.706–2.816 0.331 1.055 0.508–2.191 0.885
EYA4 protein expressiona (≤3.4 vs. >3.4) 2.635 1.684–4.122 <0.001 2.730 1.727–4.314 <0.001
CA19‑9 (>37 U/L vs. ≤37 U/L) 1.753 1.107–2.778 0.017 1.955 1.214–3.147 0.006
CEA (>5 µg/L vs. ≤5 µg/L) 1.665 1.077–2.574 0.022 1.764 1.128–2.758 0.013
Size of tumor (≤5 cm vs. >5 cm) 0.983 0.631–1.529 0.938 1.047 0.667–1.643 0.841
Number of tumors (multiple vs. single) 2.469 1.521–4.006 <0.001 2.921 1.809–4.717 <0.001
Vascular invasion (yes vs. no) 1.803 0.899–3.616 0.097 2.049 1.053–3.989 0.055
Adjacent organ invasion (yes vs. no) 2.489 1.388–4.462 0.002 3.328 1.851–5.984 <0.001
Lymph node metastasis (yes vs. no) 2.410 1.558–3.728 <0.001 2.279 1.460–3.558 <0.001
Tumor differentiation (poor vs. moderate vs. well) 2.009 1.366–2.953 <0.001 2.272 1.540–3.353 <0.001
Multivariate
EYA4 protein expressiona (≤3.4 vs. >3.4) 1.730 1.060–2.823 0.028 1.781 1.093–2.902 0.021
Number of tumors (multiple vs. single) 2.008 1.201–3.357 0.008 2.494 1.508–4.124 <0.001
Adjacent organ invasion (yes vs. no) 2.325 1.238–4.367 0.009 3.765 1.954–7.253 0.001
Lymph node metastasis (yes vs. no) 1.919 1.181–3.120 0.009 1.798 1.106–2.921 0.018
Tumor differentiation (poor vs. moderate vs. well) 2.053 1.301–3.238 0.002 2.530 1.578–4.055 <0.001
Fig. 3 Tumor‑suppressive effects of EYA4 gene expression in vitro. a EYA4‑overexpressing transfectants RBE‑EYA4 and SSP‑EYA4 show significantly 
elevated expression levels of EYA4 mRNA (*P = 0.001 and *P < 0.001, respectively) as well as protein levels. b Overexpression of the EYA4 gene sig‑
nificantly suppressed the growth rate of RBE‑EYA4 and SSP‑EYA4 compared with RBE‑vector and SSP‑vector, respectively (both *P = 0.001). c EYA4‑
overexpressing transfectants show weaker capacity in foci formation than their vector control transfectants (both *P < 0.001). d EYA4 overexpression 
resulted in weakened invasiveness of transfectants (both *P < 0.001)
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EYA4 gene functioned as a molecular prognostic marker 
in ICC.
Recently, the EYA4 gene was found to be hypermeth-
ylated in some malignancies, including esophageal, 
colorectal, and lung carcinoma [18–21]. In our previous 
study, we showed that the EYA4 gene was hypermethyl-
ated with a down-regulated expression in HCC, and that 
low EYA4 expression was an independent unfavorable 
prognostic factor [15]. In the present study, we showed 
that EYA4 expression was notably lower in ICC tissues 
than in adjacent non-tumorous tissues. Additionally, 
EYA4 expression in ICC with multiple tumors or with 
lymph node metastases was significantly lower than that 
in ICC with single tumors or without lymph node metas-
tases, respectively. Multivariate analysis showed that low 
EYA4 expression was an independent unfavorable prog-
nostic factor for DFS and OS. These results suggest that 
the EYA4 gene might be related to ICC tumorigenesis 
and progression and function as a molecular prognostic 
marker.
Fig. 4 Intratumoral injection of EYA4‑expressing plasmids suppressed RBE‑ and SSP‑25‑derived xenograft tumor growth in vivo. a Intra‑tumoral 
injection of EYA4 plasmids (EYA4 group) led to slower tumor growth at nearly all examined time points compared with vector and blank groups 
(P = 0.001 and P = 0.033, respectively); b After six treatments by intratumoral injection, the volume of tumors in the EYA4 group (bottom) was sig‑
nificantly smaller than those in the vector (middle) and blank groups (top, P = 0.001 for RBE and P = 0.011 for SSP, respectively). c Tumor weights in 
the EYA4 group were significantly smaller than those in vector and blank groups (*P = 0.004 for RBE and *P = 0.036 for SSP, respectively). d Adverse 
effects of EYA4‑expressing plasmid treatment were evaluated by mice body weight, and no differences are observed among EYA4, vector and blank 
groups (P = 0.617 for RBE and P = 0.924 for SSP, respectively)
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To investigate the biological functions of the EYA4 
gene on ICC, two stable EYA4-overexpressing transfect-
ants (RBE-EYA4 and SSP-EYA4) were established. Com-
pared with their corresponding vector controls, both 
RBE-EYA4 and SSP-EYA4 had significantly lower pro-
liferation, foci forming, and invasiveness abilities. These 
results showed that overexpression of the EYA4 gene 
could suppress growth of ICC cells in  vitro. To further 
evaluate the biological effects of the EYA4 gene on ICC 
in vivo, intra-tumoral injections of EYA4-expressing plas-
mids were administered to treat xenograft RBE and SSP-
25 tumors in NOD/SCID mice. Compared with vector 
plasmid and blank control groups, intra-tumoral injec-
tion of EYA4-expressing plasmids significantly inhibited 
the growth of both xenograft RBE and SSP-25 tumors in 
NOD/SCID mice. These results showed that overexpres-
sion of the EYA4 gene could suppress the growth of ICC. 
Additionally, it suggested that EYA4 might function as a 
tumor suppressor gene in ICC. Our results were consist-
ent with those reported by Kim et  al. [20]. They found 
that EYA4 overexpression could inhibit the growth of 
colorectal cancer cells both in  vitro and in  vivo. Using 
genome-wide expression array, they screened out abnor-
mal expression of genes involved in the Wnt, mitogen-
activated protein kinase (MAPK), and local adhesion 
signal pathways in EYA4-overexpressing colorectal can-
cer cells. Among these genes, they found that dickkopf 
WNT signaling pathway inhibitor 1 (DKK1), an impor-
tant inhibitor of the Wnt pathway, was significantly over-
expressed in EYA4-overexpressing colorectal cancer cells; 
therefore, they speculated that EYA4 could act as a tumor 
suppressor gene and inhibit the Wnt signal pathway in 
colorectal cancer cells by up-regulating DKK1 [20]. How-
ever, further investigation is required to elucidate the 
mechanisms of EYA4 in suppressing ICC.
In summary, we showed that the EYA4 gene was a 
novel molecular prognostic marker for ICC and could 
inhibit the growth of ICC cells in  vitro and vivo. How-
ever, the mechanism of the EYA4 gene in inhibiting ICC 
cell growth remains unclear, and additional studies are 
needed.
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